Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?
Executive Summary
Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call
You may also be interested in...
Wyeth, Baxter Recombinant Factor VIII Licenses Subject Of FTC Inquiry
Wyeth and Baxter have been contacted by the Federal Trade Commission to provide documentation regarding licensing agreements for their recombinant factor VIII hemophilia A products
Wyeth, Baxter Recombinant Factor VIII Licenses Subject Of FTC Inquiry
Wyeth and Baxter have been contacted by the Federal Trade Commission to provide documentation regarding licensing agreements for their recombinant factor VIII hemophilia A products
Bayer Sheds R&D Projects Ahead Of Joint Venture, Is Flexible On Control
Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12